Back to Agenda
Hosted Session/Non-CE: Case Study Spotlight hosted by IQVIA: Ensuring Labeling Harmonization Amidst a Legal Entity Change
Session Chair(s)
Sponsored Sessions
United States
The success and safety of drug products heavily depend on an efficient labeling team, particularly during a legal entity change such as a merger, acquisition, or marketing authorization transfer. Such changes can pose compliance risks, leading to potential safety risks, product recalls, and brand damage. However, the development of new labels can be smooth with a well-planned strategy, timeline, and data transfers that follow both companies’ regulations.
Successful labeling harmonization relies on a gap analysis that examines the labeling practices of both companies and identifies any discrepancies. This allows for the creation of a strategy that addresses these deviations and mitigates any compliance risk. If the labeling team lacks the ability to manage this additional workload, partnering with a vendor experienced in legal entity change procedures could be beneficial. The process begins with reviewing the steps to develop new, compliant labels, followed by identifying a strategy that aligns with the company’s goal with a patient-centric approach.
Featured Topics:
- Impact Assessment and Gap Analysis
- Designin a Labeling Strategy
- Data Transfer
- Submission to Health Authorities
- New Label Implementation
- Using LLM, NLP, and Automated Label Text Comparison Technology
Speaker(s)
Rama Mohan Rao Chikkam
IQVIA, United States
Senior Director, Regulatory Affairs
Kiran Chinnalla
IQVIA, India
Director, Product Manager - Regulatory Affairs
Have an account?